Drugs / adipose-derived stem cells
adipose-derived stem cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01803347 | Feb 2013 → Oct 2017 | anal fistula | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | adipose-derived stem cells | “The feasibility and safety of stem cell-based therapy with expanded adipose-derived stem cells (ASCs) has been investigated in a phase I clinical trial.” PMID 19273960 ↗ Jan 2009 |
| Known as | ASCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01803347 ↗ |
| Known as | expanded adipose-derived stem cells | “The feasibility and safety of stem cell-based therapy with expanded adipose-derived stem cells (ASCs) has been investigated in a phase I clinical trial.” PMID 19273960 ↗ Jan 2009 |
| Route | Other | “randomly assigned to intralesional treatment with fibrin glue or fibrin glue plus 20 million ASCs” PMID 19273960 ↗ Jan 2009 |